The Role of Preoperative Subconjunctival Bevacizumab on Recurrence Rate of Primary Pterygium Dawood Yousif Farhan1,* Department of Ophthalmology, College of Medicine, University of Anbar, Anbar, Iraq 1Department of Ophthalmology, Ibn Al Haitham Teaching Eye Hospital, Baghdad, Iraq *Corresponding Author: Yousif Farhan Dawood, ABHS (CABOphth), ICO (Camb), MD Department of Ophthalmology, Ibn Al Haitham Teaching Eye Hospital, Baghdad, Iraq, Email: yf_ds@yahoo.com
Online published on 23 December, 2019. Abstract To assess the value of one week preoperative subconjunctival injection of bevacizumab on the surgical management of primary pterygia and also to evaluate the rate of recurrence after excision. This is experimental clinical trial included110 eyes of 110 patients (59 males and 51 females) with a mean age of (49.62 ± 16.54 years), range (27–68) had primary pterygia. The dose of bevacizumab was a 1.25 mg (0.05 ml) one week before pterygium surgery. Surgery was done using excision with direct conjunctival suturing technique. All pterygia were followed up for 6 months. Top Keywords Bevacizumab, P terygium, Recurrence. Top |